CA2865774A1 - Psma as a biomarker for androgen activity in prostate cancer - Google Patents
Psma as a biomarker for androgen activity in prostate cancer Download PDFInfo
- Publication number
- CA2865774A1 CA2865774A1 CA2865774A CA2865774A CA2865774A1 CA 2865774 A1 CA2865774 A1 CA 2865774A1 CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A1 CA2865774 A1 CA 2865774A1
- Authority
- CA
- Canada
- Prior art keywords
- psma
- imaging
- patient
- prostate cancer
- measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 46
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 46
- 239000003098 androgen Substances 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title claims abstract description 18
- 239000000090 biomarker Substances 0.000 title abstract description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims abstract description 154
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims abstract description 152
- 230000014509 gene expression Effects 0.000 claims abstract description 54
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract description 14
- 239000000051 antiandrogen Substances 0.000 claims abstract description 14
- 230000002280 anti-androgenic effect Effects 0.000 claims abstract description 13
- 238000003384 imaging method Methods 0.000 claims description 37
- 238000005259 measurement Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 25
- 238000002600 positron emission tomography Methods 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 14
- 238000002591 computed tomography Methods 0.000 claims description 12
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 11
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000012634 optical imaging Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 230000009870 specific binding Effects 0.000 claims description 6
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 210000004412 neuroendocrine cell Anatomy 0.000 claims description 2
- 201000007676 prostate small cell carcinoma Diseases 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 108010080146 androgen receptors Proteins 0.000 abstract description 51
- 102000001307 androgen receptors Human genes 0.000 abstract description 51
- 210000004027 cell Anatomy 0.000 abstract description 36
- 210000002307 prostate Anatomy 0.000 abstract description 6
- 230000003827 upregulation Effects 0.000 abstract description 6
- 238000003364 immunohistochemistry Methods 0.000 abstract description 4
- 238000002679 ablation Methods 0.000 abstract description 3
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 abstract description 2
- 238000011503 in vivo imaging Methods 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 239000012894 fetal calf serum Substances 0.000 description 10
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 9
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101150029129 AR gene Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241001590720 Anania Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003331 infrared imaging Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 101000834245 Danio rerio Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 1
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- -1 OCT compound Chemical class 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 102000046818 human AR Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940000207 selenious acid Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604039P | 2012-02-28 | 2012-02-28 | |
| US61/604,039 | 2012-02-28 | ||
| PCT/US2013/000051 WO2013130177A1 (en) | 2012-02-28 | 2013-02-27 | Psma as a biomarker for androgen activity in prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2865774A1 true CA2865774A1 (en) | 2013-09-06 |
Family
ID=49083148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865774A Abandoned CA2865774A1 (en) | 2012-02-28 | 2013-02-27 | Psma as a biomarker for androgen activity in prostate cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130315830A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2819704A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015508903A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2865774A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202256A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013130177A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| MX2018001566A (es) | 2015-08-07 | 2019-04-25 | Imaginab Inc | Construcciones de union a antigeno para moleculas diana. |
| JP2020505034A (ja) | 2017-01-20 | 2020-02-20 | ジュノ セラピューティクス ゲーエムベーハー | 細胞表面コンジュゲートならびに関連する細胞組成物および方法 |
| AU2018250336B2 (en) | 2017-04-07 | 2025-02-20 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
| CA3113080A1 (en) * | 2018-09-28 | 2020-04-02 | Imaginab, Inc. | Cd8 imaging constructs and methods of use thereof |
| WO2022114675A1 (ko) * | 2020-11-24 | 2022-06-02 | 한국과학기술연구원 | 전립선암 진단을 위한 바이오마커, 이들의 조합, 및 이의 용도 |
| EP4267969A4 (en) * | 2020-12-22 | 2025-02-12 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE337011T1 (de) * | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
| AU2007227195A1 (en) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and Ly6 E: targets for cancer diagnosis and therapy |
| EP2209498A2 (en) * | 2007-10-03 | 2010-07-28 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| US20100047166A1 (en) * | 2008-08-20 | 2010-02-25 | Kanner Steven B | Antibodies and related molecules that bind to 58p1d12 proteins |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| EP4420730A3 (en) * | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| WO2010119001A1 (en) * | 2009-04-14 | 2010-10-21 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
| EP2817629A4 (en) * | 2012-02-24 | 2016-01-13 | Univ Cornell | INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER |
-
2013
- 2013-02-27 HK HK15102796.5A patent/HK1202256A1/xx unknown
- 2013-02-27 WO PCT/US2013/000051 patent/WO2013130177A1/en not_active Ceased
- 2013-02-27 JP JP2014559890A patent/JP2015508903A/ja active Pending
- 2013-02-27 US US13/778,306 patent/US20130315830A1/en not_active Abandoned
- 2013-02-27 EP EP13754565.3A patent/EP2819704A4/en not_active Withdrawn
- 2013-02-27 CA CA2865774A patent/CA2865774A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130315830A1 (en) | 2013-11-28 |
| EP2819704A4 (en) | 2015-10-21 |
| JP2015508903A (ja) | 2015-03-23 |
| EP2819704A1 (en) | 2015-01-07 |
| HK1202256A1 (en) | 2015-09-25 |
| WO2013130177A1 (en) | 2013-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency | |
| Yee et al. | Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression | |
| US20130315830A1 (en) | PSMA as a BioMarker for Androgen Activity in Prostate Cancer | |
| Fu et al. | Exosomal TRIM3 is a novel marker and therapy target for gastric cancer | |
| Surowiak et al. | ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome | |
| Cochrane et al. | Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide | |
| US20250230259A1 (en) | Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability | |
| Nickkho-Amiry et al. | Peroxisome proliferator–activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma | |
| Makris et al. | Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study | |
| Wang et al. | Astrocyte elevated gene-1 is associated with metastasis in head and neck squamous cell carcinoma through p65 phosphorylation and upregulation of MMP1 | |
| Long et al. | Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression | |
| Sammarco et al. | Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients | |
| Salehi et al. | Biomarkers of pituitary neoplasms: a review (Part II) | |
| AU2016270686A1 (en) | Quantifying Her2 protein for optimal cancer therapy | |
| Lopes et al. | Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population | |
| Gu et al. | Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer | |
| Feng et al. | Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis | |
| Chocarro-Calvo et al. | Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression | |
| Li et al. | RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis | |
| Lang et al. | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy | |
| Gaber et al. | Obesity increases DNA damage in the breast epithelium | |
| Zhang et al. | Secreted CLU is associated with the initiation of triple-negative breast cancer | |
| US7718393B2 (en) | Method for determining the efficacy of an anthracycline anticancer agent | |
| Huang et al. | Clinicopathological and cellular signature of PAK1 in human bladder cancer | |
| WO2017172734A1 (en) | Treating cancer metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180226 |
|
| FZDE | Discontinued |
Effective date: 20210831 |